Today, a Director at Heron Therapeutics (HRTX), John Poyhonen, bought shares of HRTX for $52.65K.
Following this transaction John Poyhonen’s holding in the company was increased by 30% to a total of $228K. Following John Poyhonen’s last HRTX Buy transaction on January 23, 2017, the stock climbed by 4.9%.
See today’s analyst top recommended stocks >>
Based on Heron Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $31.6 million and GAAP net loss of $63.01 million. In comparison, last year the company earned revenue of $11.57 million and had a GAAP net loss of $52.27 million. Currently, Heron Therapeutics has an average volume of 721.2K.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $45.20, reflecting a 157.7% upside. Starting in August 2018, HRTX received 45 Buy ratings in a row. Five different firms, including Cantor Fitzgerald and Cowen & Co., currently also have a Buy rating on the stock.
The insider sentiment on Heron Therapeutics has been positive according to 14 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
John Poyhonen’s trades have generated a 44.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011.
